- Home
- FRHC vs NUVL Comparison
FRHC vs NUVL Comparison
Compare FRHC & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRHC
- NUVL
- Stock Information
- Founded
- FRHC 1981
- NUVL 2017
- Country
- FRHC Kazakhstan
- NUVL United States
- Employees
- FRHC N/A
- NUVL N/A
- Industry
- FRHC Investment Bankers/Brokers/Service
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- FRHC Finance
- NUVL Health Care
- Exchange
- FRHC Nasdaq
- NUVL Nasdaq
- Market Cap
- FRHC 7.2B
- NUVL 6.7B
- IPO Year
- FRHC N/A
- NUVL 2021
- Fundamental
- Price
- FRHC $131.50
- NUVL $87.30
- Analyst Decision
- FRHC
- NUVL Strong Buy
- Analyst Count
- FRHC 0
- NUVL 10
- Target Price
- FRHC N/A
- NUVL $112.60
- AVG Volume (30 Days)
- FRHC 86.1K
- NUVL 350.8K
- Earning Date
- FRHC 02-07-2025
- NUVL 11-12-2024
- Dividend Yield
- FRHC N/A
- NUVL N/A
- EPS Growth
- FRHC 11.75
- NUVL N/A
- EPS
- FRHC 5.68
- NUVL N/A
- Revenue
- FRHC $1,306,629,000.00
- NUVL N/A
- Revenue This Year
- FRHC N/A
- NUVL N/A
- Revenue Next Year
- FRHC N/A
- NUVL N/A
- P/E Ratio
- FRHC $23.51
- NUVL N/A
- Revenue Growth
- FRHC 68.86
- NUVL N/A
- 52 Week Low
- FRHC $64.00
- NUVL $61.80
- 52 Week High
- FRHC $134.00
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- FRHC 69.97
- NUVL 36.14
- Support Level
- FRHC $117.95
- NUVL $84.64
- Resistance Level
- FRHC $134.00
- NUVL $89.31
- Average True Range (ATR)
- FRHC 3.25
- NUVL 2.82
- MACD
- FRHC 0.31
- NUVL -0.72
- Stochastic Oscillator
- FRHC 84.42
- NUVL 20.93
About FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.